Better Therapeutics Stock EBITDA
| BTTXDelisted Stock | USD 0.73 0.04 5.19% |
Better Therapeutics fundamentals help investors to digest information that contributes to Better Therapeutics' financial success or failures. It also enables traders to predict the movement of Better OTC Stock. The fundamental analysis module provides a way to measure Better Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Better Therapeutics otc stock.
Better |
Better Therapeutics OTC Stock EBITDA Analysis
Better Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Better Therapeutics EBITDA | (29.18 M) |
Most of Better Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Better Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Better Therapeutics reported earnings before interest,tax, depreciation and amortization of (29.18 Million). This is 103.33% lower than that of the Biotechnology sector and 129.13% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.75% higher than that of the company.
Better EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Better Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Better Therapeutics could also be used in its relative valuation, which is a method of valuing Better Therapeutics by comparing valuation metrics of similar companies.Better Therapeutics is currently under evaluation in ebitda category among its peers.
Better Fundamentals
| Return On Equity | -10.22 | ||||
| Return On Asset | -0.95 | ||||
| Current Valuation | 8.83 M | ||||
| Shares Outstanding | 54.52 M | ||||
| Shares Owned By Insiders | 53.41 % | ||||
| Shares Owned By Institutions | 2.94 % | ||||
| Number Of Shares Shorted | 2.13 M | ||||
| Price To Book | 2.29 X | ||||
| Price To Sales | 49,559 X | ||||
| Gross Profit | (674 K) | ||||
| EBITDA | (29.18 M) | ||||
| Net Income | (31.57 M) | ||||
| Cash And Equivalents | 29.68 M | ||||
| Cash Per Share | 1.25 X | ||||
| Total Debt | 14.88 M | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 5.23 X | ||||
| Book Value Per Share | (0.24) X | ||||
| Cash Flow From Operations | (26.08 M) | ||||
| Short Ratio | 0.94 X | ||||
| Earnings Per Share | (1.10) X | ||||
| Target Price | 5.25 | ||||
| Number Of Employees | 54 | ||||
| Beta | 2.35 | ||||
| Market Capitalization | 1.12 M | ||||
| Total Asset | 22.94 M | ||||
| Retained Earnings | (111.5 M) | ||||
| Working Capital | 4.95 M | ||||
| Z Score | -10.7 | ||||
| Net Asset | 22.94 M |
About Better Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Better Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Better Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Better Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Better OTC Stock
If you are still planning to invest in Better Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Better Therapeutics' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |